REAL-WORLD HEALTHCARE RESOURCE UTILIZATION IN FIRST-LINE TREATED JAPANESE PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER
Author(s)
Kazuko Taniguchi, MS1, Keisuke Aoe, MD2, Kohei Fujita, PhD3, kodai kawamura, MD, PhD4, Ichiro Nakachi, PhD, MD5, Kazutoshi Isobe, MD6, Hirotaka Matsumoto, MD7, Yasushi Goto, MD8, Hiroshi Nokihara, MD9, Melissa L. Santorelli, BA, MPH, PhD10, Shuji Nagasaki, PhD11, Taizo Matsuki, MPH, PhD12;
1MSD K.K., Assciate Director, Tokyo, Japan, 2Kasaoka Central Hospital, Kasaoka, Japan, 3NHO Kyoto Medical Center, Kyoto, Japan, 4Saiseikai Kumamoto Hospital, kumamoto, Japan, 5Saiseikai Utsunomiya Hospital, Utsunomiya, Japan, 6Toho University Omori Medical Center, setagaya-ku, Japan, 7Hyogo Prefectual Amagasaki General Medical Center, Amagasaki, Japan, 8National Cancer Center Hospital, Tokyo, Japan, 9National Center for Global Health and Medicine, Tokyo, Japan, 10Merck, Rahway, NJ, USA, 11MSD K.K., Chiyoda-ku, Japan, 12MSD K.K., Urayasu, Japan
1MSD K.K., Assciate Director, Tokyo, Japan, 2Kasaoka Central Hospital, Kasaoka, Japan, 3NHO Kyoto Medical Center, Kyoto, Japan, 4Saiseikai Kumamoto Hospital, kumamoto, Japan, 5Saiseikai Utsunomiya Hospital, Utsunomiya, Japan, 6Toho University Omori Medical Center, setagaya-ku, Japan, 7Hyogo Prefectual Amagasaki General Medical Center, Amagasaki, Japan, 8National Cancer Center Hospital, Tokyo, Japan, 9National Center for Global Health and Medicine, Tokyo, Japan, 10Merck, Rahway, NJ, USA, 11MSD K.K., Chiyoda-ku, Japan, 12MSD K.K., Urayasu, Japan
OBJECTIVES: First-line (1L) immunotherapy (IO) for advanced non-small cell lung cancer (NSCLC) is approved in Japan, but data regarding healthcare resource utilization (HCRU) post IO-chemotherapy introduction is limited. This study characterizes HCRU in advanced NSCLC by regimen types after IO expansion in Japan.
METHODS: This prospective observational study was conducted at 23 centers in Japan. Eligible patients were ≥20 years old with confirmed advanced NSCLC lacking actionable genomic alterations, initiating 1L therapy outside clinical trials between Nov 2019-Dec 2021 and consented to participate in the study. Minimum potential follow-up was 2 years. HCRU outcomes assessed in this study comprised hospitalizations, including emergency room (ER) admissions and outpatient visits.
RESULTS: The overall population included 987 patients: 16% received IO-monotherapy (IO-mono), 48% IO-chemotherapy (IO-chemo), 19% platinum doublet, and 17% other treatments as 1L therapy. Hospital admissions occurred at 3.34, 5.06, and 7.11 per 100 patient-weeks for patients that received IO-mono, IO-chemo, and platinum doublet, respectively. Proportion of patients with at least one hospital admission due to systemic treatment was 74.8%, with IO-mono therapy, 88.5% for IO-chemo and 87.8% for platinum doublet. Median hospitalization duration during 1L therapy was 13, 12, and 14 days for IO-mono, IO-chemo, and platinum doublet, respectively. ER admission occurred in 8.4% of IO-mono patients, 7.8% of IO-chemo, and 8.5% of platinum doublet patients. Frequency of ER use was 0.16, 0.15, 0.39 per 100 patient-weeks for IO-mono, IO-chemo, and platinum doublet respectively. Outpatient visits were 32.8 per 100 patient-weeks with IO-mono therapy, 37.3 for IO-chemo and 43.7 for the platinum doublet. Outpatient infusion center visits were 15.4, 18.1, and 13.1 per 100 patient-weeks for IO-mono, IO-chemo, and the platinum doublet, respectively.
CONCLUSIONS: Our results are consistent with no increase in HCRU burden following expanded IO access for advanced NSCLC in Japan, with continued movement toward outpatient treatment administration and decreased hospitalizations.
METHODS: This prospective observational study was conducted at 23 centers in Japan. Eligible patients were ≥20 years old with confirmed advanced NSCLC lacking actionable genomic alterations, initiating 1L therapy outside clinical trials between Nov 2019-Dec 2021 and consented to participate in the study. Minimum potential follow-up was 2 years. HCRU outcomes assessed in this study comprised hospitalizations, including emergency room (ER) admissions and outpatient visits.
RESULTS: The overall population included 987 patients: 16% received IO-monotherapy (IO-mono), 48% IO-chemotherapy (IO-chemo), 19% platinum doublet, and 17% other treatments as 1L therapy. Hospital admissions occurred at 3.34, 5.06, and 7.11 per 100 patient-weeks for patients that received IO-mono, IO-chemo, and platinum doublet, respectively. Proportion of patients with at least one hospital admission due to systemic treatment was 74.8%, with IO-mono therapy, 88.5% for IO-chemo and 87.8% for platinum doublet. Median hospitalization duration during 1L therapy was 13, 12, and 14 days for IO-mono, IO-chemo, and platinum doublet, respectively. ER admission occurred in 8.4% of IO-mono patients, 7.8% of IO-chemo, and 8.5% of platinum doublet patients. Frequency of ER use was 0.16, 0.15, 0.39 per 100 patient-weeks for IO-mono, IO-chemo, and platinum doublet respectively. Outpatient visits were 32.8 per 100 patient-weeks with IO-mono therapy, 37.3 for IO-chemo and 43.7 for the platinum doublet. Outpatient infusion center visits were 15.4, 18.1, and 13.1 per 100 patient-weeks for IO-mono, IO-chemo, and the platinum doublet, respectively.
CONCLUSIONS: Our results are consistent with no increase in HCRU burden following expanded IO access for advanced NSCLC in Japan, with continued movement toward outpatient treatment administration and decreased hospitalizations.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
EE365
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
SDC: Oncology